Muddukrishna badamane sathyanarayana

Mr. Muddukrishna badamane sathyanarayana

Pharmaceutical Quality Assurance, Manipal college of Pharmaceutical sciences, Manipal, India
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Journal of Advanced Pharmaceutical Technology & Research
Verified
Journal Article
Open access
PDF file
PMPrashant B Musmade
Prashant B Musmade
LNLokesh P Nijhawan
Lokesh P Nijhawan
MJManthan Janodia
Manthan Janodia
MSMuddukrishna badamane sathyanarayana
Muddukrishna badamane sathyanarayana
KBKm Bhat
Km Bhat
NUN Udupa
N Udupa
Informed consent is an ethical and legal requirement for research involving human participants. It is the process where a participant is informed about all aspects of the trial, which are important for the participant to make a decision and after studying all aspects of the trial the participant voluntarily confirms his or her willingness to participate in a particular clinical trial and significance of the research for advancement of medical knowledge and social welfare. The concept of informed consent is embedded in the principles of Nuremberg Code, The Declaration of Helsinki and The Belmont Report. Informed consent is an inevitable requirement prior to every research involving human being as subjects for study. Obtaining consent involves informing the subject about his or her rights, the purpose of the study, procedures to be undertaken, potential risks and benefits of participation, expected duration of study, extent of confidentiality of personal identification and demographic data, so that the participation of subjects in the study is entirely voluntary. This article provides an overview of issues in informed consent: The obligations of investigator, sponsor and Institutional Review Board to protect rights and welfare of human research subjects. It discusses about the basic elements of informed consent and the process to be followed while obtaining informed consent. Some of the circumstances under which informed consent can be waived and ethical challenges faced by physicians in obtaining informed consent from subjects are also highlighted in this article.

1 January 2018 in Research Journal of Pharmacy and Technology
Verified
Journal Article
Closed access
PDF file
GMGarlapati Manideep
Garlapati Manideep
NSNazare Lobo John Shane
Nazare Lobo John Shane
GPGirish Pai
Girish Pai
MSMuddukrishna badamane sathyanarayana
Muddukrishna badamane sathyanarayana
This present UV Spectrophotometric method developed using methanol as a solvent is simple, rapid, specific, precise and sensitive to estimation Etoricoxib in bulk in day to day analysis. The method was validated as per ICH Q2R1 guideline. Etoricoxib is the newest addition to the group of Non-Steroidal Anti-Inflammatory Drugs highly selective COX-2 inhibitor. The solvent used in the entire method development and validation was methanol. The maximum wavelength of absorption was found to be 234nm. Beer's law was obeyed in the concentration range of 1 to 11μg/mL with correlation coefficient of 0.9986. The method was precise with an RSD of0.42%the LOD and LOQ were found to be 0.09μg/ml and 0.2μg/ml respectively. The method was validated for precision, linearity, accuracy and robustness and all parameters were found to be satisfactory which proves that this method can be used for routine analysis of Etoricoxib.

1 February 2018 in Data in Brief
Verified
Journal Article
Open access
MRMikal Rekdal
Mikal Rekdal
APAravind Pai
Aravind Pai
MSMuddukrishna badamane sathyanarayana
Muddukrishna badamane sathyanarayana
Etravirine is a drug used alongside other medication in the treatment of HIV and is a non-nucleoside reverse transcriptase inhibitor. It is a BCS class IV drug, having low solubility and high permeability (Drugbank, https://www.drugbank.ca/drugs/DB06414) [1]. As a result, large doses of the drug are required for treatment. Two pills have to be taken twice a day, making it a "pill burden" (Intelence, http://www.intelence.com/hcp/dosing/administration-options) [2]. Therefore, attempts of co-crystallizing Etravirine are attractive as the solubility of the drug tends to increase in this solid form (Schultheiss and Newman, 2009) [3]. In this study Etravirine co-crystals were synthesized in the molar ratios 1:1, 1:2 and 2:1 with L-tartaric acid as the co-former. Both slow evaporation and physical mixture was performed to mix the components. DSC values of final products are presented as well as FTIR spectra to observe the altered intermolecular interactions. A chemical stability test was performed after seven days using area under curve data from an HPLC instrument.

17 May 2021 in Indian Journal of Pharmaceutical Education and Research
Verified
Journal Article
Open access
KSKevita D Souza
Kevita D Souza
ASAlisha Syeda
Alisha Syeda
PKParnika Khatal
Parnika Khatal
MSMuddukrishna badamane sathyanarayana
Muddukrishna badamane sathyanarayana
VSVasantharaju Vasantharaju Sg
Vasantharaju Vasantharaju Sg

7 July 2024 in International Journal of Applied Pharmaceutics
Verified
Journal Article
Open access
PDF file
GNG. Niharika
G. Niharika
SASyeda Alisha Md Isha Ali
Syeda Alisha Md Isha Ali
KBKrishnamurthy Bhat
Krishnamurthy Bhat
BHBasavaraj S. Hadapad
Basavaraj S. Hadapad
MSMuddukrishna badamane sathyanarayana
Muddukrishna badamane sathyanarayana
SVS. G. Vasantharaju
S. G. Vasantharaju
Objective: The concept of shelf life of classical Ayurvedic formulations is clearly defined in the classical literature of Ayurveda. Considering the Ayurveda development and recent gazette notification of 161-B, it is important to evaluate the stability of the Ayurvedic products based on scientific evidence. The study aims to evaluate the stability and estimate the shelf life of Vacha churna by using the marker Beta-asarone. The chemical marker of the Vacha churna has been identified as Beta-asarone. Methods: A stability-indicating RP-HPLC method has been developed and validated for Beta-asarone. The method utilises a Stationary phase C18 column and a mobile phase composed of acetonitrile and ammonium acetate buffer. Beta-asarone underwent various stress conditions like acid and base hydrolysis, oxidation, temperature and photolytic degradation. The Vacha churna has been stored in a stability chamber for both accelerated and long-term testing. The formulation was taken at specific time intervals and the marker content was analysed using RP-HPLC. Results: Beta-asarone was eluted at 6.03 min. The linear regression equation was found to be y = 28211x-1349.3 with a R2 of 0.9991. Stress studies confirmed the absence of co-eluting peaks and degradants under various stress conditions. Based on the analysis of Beta-asarone marker content, the shelf life of Vacha churna was estimated to be 62.40 mo. Conclusion: Data from RP-HPLC method and stability studies can be employed for routine commercial stability assessments. Due to the absence of a Pharmacopoeial RP-HPLC method, local Ayurvedic manufacturers can utilise the developed method. The investigated shelf life thus serves as a medium of chemical stability based on the scientific evidence.

7 May 2025 in International Journal of Applied Pharmaceutics
Verified
Journal Article
Open access
PDF file
SASUPRAJA ATHERIYA
SUPRAJA ATHERIYA
GRGundawar Ravi
Gundawar Ravi
TPTanvi Painginkar
Tanvi Painginkar
GKGirish Pai K.
Girish Pai K.
VLVirendra Ligade
Virendra Ligade
MSMuddukrishna badamane sathyanarayana
Muddukrishna badamane sathyanarayana
Chronic Obstructive Pulmonary Disorder (COPD) is a diverse lung ailment characterized by persistent respiratory symptoms such as coughing, dyspnea, sputum formation, and worsening that causes increased airflow limitation. Globally, COPD ranks third in 2019 and is responsible for 3.23 million deaths. It is a health problem that is brought on by inflammation in the lungs. The respiratory system comprises the trachea, bronchi, larynx, paranasal sinuses, and two lungs. COPD and other Respiratory Disorders (RDs) have dominated research. This review emphasizes the potential of novel treatment strategies for COPD, highlighting advanced therapeutic approaches. It addresses the ongoing challenges associated with the effective delivery of pharmaceuticals to targeted sites while aiming to achieve optimal therapeutic outcomes with reduced dosages. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) Report 2024 categorizes COPD treatments into pharmacological and non-pharmacological interventions. Pharmacological therapies aim to alleviate symptoms, enhance exercise tolerance, reduce exacerbations, and improve health outcomes. These include antibiotics, Long-Acting Beta-Agonist (LABA), Short-Acting Beta-Agonist (SABA), Long-Acting Muscarinic-Antagonists (LAMA), Short-Acting Muscarinic-Antagonists (SAMA), Inhaled Corticosteroids (ICS), and bronchodilators in various formulations. The report also reviews inhaler types and highlights the role of nanoscale drug delivery systems in detecting drug particle deposition in the respiratory tract, along with the characterization and classification of Nanoparticles (NPs) in nanomedicine. In conclusion, contemporary nanoparticles enhance biodistribution, optimize pharmacokinetics, and promote physiological stimulation. They also reduce toxicity and increase the therapeutic index, thereby facilitating the transformation of medication administration for chronic respiratory disorders.